Literature DB >> 3444038

Mitral valve prolapse in patients with anorexia nervosa. Two-dimensional echocardiographic study.

Y Oka1, T Ito, S Matsumoto, H Suematsu, E Ogata.   

Abstract

To examine the prevalence of mitral valve prolapse (MVP) and to define the mechanisms of its development in patients with anorexia nervosa, we studied the cardiac function of 23 patients with anorexia nervosa by two-dimensional (2-D) echocardiography. MVP was present in 19 of 23 patients (82.6%), 10 having double MVP in both the anterior and posterior mitral leaflets and 9 having a single MVP in the anterior leaflet. There was no difference in echocardiographic parameters between the MVP(+) and MVP(-) groups. The heart rate was lower in the double MVP group (46.3 +/- 8.1; mean +/- SD) than in the non MVP group (64.0 +/- 6.3; p less than 0.01) and the single MVP group (55.9 +/- 10.9; p less than 0.05). The presence of bradycardia in these patients suggests an increase in vagal tone. The present study suggests that the incidence of MVP in anorexia nervosa is among the highest compared with its incidence in association with any other disorders, and an increase in vagal tone may be responsible for the development of MVP in patients with anorexia nervosa.

Entities:  

Mesh:

Year:  1987        PMID: 3444038     DOI: 10.1536/ihj.28.873

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  3 in total

1.  Preventing mitral valve prolapse in anorexia nervosa.

Authors:  T O Cheng
Journal:  CMAJ       Date:  1989-08-01       Impact factor: 8.262

2.  Vagal nerve stimulation reduces anterior mitral valve leaflet stiffness in the beating ovine heart.

Authors:  Julia C Swanson; Gaurav Krishnamurthy; Akinobu Itoh; John-Peder Escobar Kvitting; Wolfgang Bothe; D Craig Miller; Neil B Ingels
Journal:  J Biomech       Date:  2012-06-15       Impact factor: 2.712

Review 3.  [Anesthesia in patients with anorexia nervosa and bulimia nervosa].

Authors:  J Zenker; U Hagenah; R Rossaint
Journal:  Anaesthesist       Date:  2010-03       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.